TSE:RVX

Resverlogix Q1 2026 Earnings Results & Report

Resverlogix logo
C$0.08 0.00 (0.00%)
As of 03:27 PM Eastern

Resverlogix reported Q1 2026 earnings on May 15, 2026. The company reported EPS of C$0.01.

Earnings Announcement Details

Quarter
Q1 2026
Report Date
Time
After Market Closes

Resverlogix EPS Results

Actual EPS
C$0.01
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Resverlogix Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

Resverlogix Q1 2026 Earnings FAQ

Resverlogix (TSE:RVX) reported earnings of C$0.01 per share for Q1 2026. The report was announced on Friday, May 15, 2026.

Resverlogix Earnings Headlines

Today's free pick (on me)
Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one lesser known company. With plans filed for 1,000,000 new satellites, that licensing fee could scale dramatically. Analyst Dylan says the stock could move by December 8th.tc pixel
See More Resverlogix Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Resverlogix? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Resverlogix and other key companies, straight to your email.

About Resverlogix

Founded in 2001, Resverlogix (TSE:RVX) is a Calgary based late-stage biotechnology company, and a world leader in epigenetics, with the goal of developing first-in-class therapies for the benefit of patients with chronic disease. Resverlogix is developing a new class of epigenetic therapies designed to regulate the expression of disease-causing genes. We aim to improve patients' lives by restoring biological functions - altered by serious illnesses such as cardiovascular disease - back to a healthier state. The Company's clinical program is focused on evaluating the lead epigenetic candidate apabetalone for the treatment of cardiovascular disease, associated comorbidities, and post COVID-19 conditions.

View Resverlogix Profile